Esophageal Cancer Panel Sequencing

Description of Esophageal Cancer

Esophageal cancer is the 8th most common cancer and 6th leading cause of cancer-related deaths in the world. The overall prognosis of esophageal cancer is poor with a 5-year survival that ranges from 15 to 25%. However, improved patient outcomes have been reported when esophageal cancer is diagnosed in its early stages. Cancers of the esophagus are primarily categorized into two subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Although the incidence of esophageal adenocarcinoma has increased rapidly, esophageal squamous cell carcinoma remains the predominant form of esophageal cancer worldwide and accounts for 80% of all cases. The accumulation of genetic alterations has a pivotal role during malignant progression of normal esophageal squamous mucosa to esophageal squamous cell carcinoma. Studies implicate a number of well-known tumor suppressor genes and oncogenes, such as TP53, CDKN2A, PIK3CA, RB1 and genes within the receptor tyrosine kinase/mitogen-activated protein kinase pathways.

To better understand the relationship between the mutation of esophageal cancer-related genes and the molecular biology mechanism of esophageal cancer, CD Genomics utilizes targeted NGS sequencing technology and offers a comprehensive library of esophageal cancer panel. If necessary, you can choose genes that fit your requirements.

Gene List of Esophageal Cancer Panel

AKT1	ATRX	BRAF	CDK6	CDKN2A	CIC	CTNNB1	DDX3X	EGFR	FUBP1
H3F3A	HRAS	IDH1	IDH2	KLF4	KRAS	MET	MYC	MYCN	NF1
NF2	NRAS	PIK3CA	PTCH1	PTEN	RB1	SETD2	SMO	TERT	TP53

Highlights of Esophageal Cancer Panel Sequencing Service

Target-enrichment sequencing by Illumina provides extremely high depth (average depth > 1000x) with lower costs.
High coverage uniformity ensures the sequencing data more efficiency.
SNVs, indels, and even low frequency variations can be detected.
Strict quality control throughout the pipeline workflow to ensure the accuracy and repeatability of the sequencing.
Fast turnaround time.

Applications of Esophageal Cancer Panel Sequencing

Cancer related mechanism studies
Biomarker discovery
Therapeutic target discovery
Drug target discovery
Discover rare mutations and detect low frequency mutations

Service Specifications

Sample Requirements

Sample types for genome DNA from tissues, whole blood, cultured cells, and formalin-fixed paraffin-embedded (FFPE) tissues.
Recommended amount: 2μg
Minimum amount: 200ng
Collection: DNA samples are stored in TE buffer or equivalent. Blood is collected by routine blood collection kits.

Sequencing

Illumina PE150
Enrichment Method: Amplicon sequencing
More than 80% of bases with a ≥Q30 quality score
Recommended sequencing depth: ≥ 500x

Bioinformatics Analysis

We provide customized bioinformatics analysis including:

Read alignment
Variant calling/Annotation

Gene Panel Workflow

CD Genomics provides the accurate and cost-effective esophageal cancer panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for esophageal cancer panel sequencing is outlined below.

Gene Panel Workflow

For more information about the esophageal cancer panel or need other amplification requirements, please contact us.

References:

Pennathur A, et al. Oesophageal carcinoma. Lancet, 2013. 381, 400-412.
Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136, 359-386.
Nikiforova M N, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol, 2016. 18, 379–387.
Aatur D S, et al. Targeted next-generation sequencing supports epidermoid metaplasia of the esophagus as a precursor to esophageal squamous neoplasia. Modern Pathology, 2017. 30, 1613–1621.

* For Research Use Only. Not for use in diagnostic procedures.